The success or failure of a oncological therapy normally only becomes clear by means of imaging methods such as PET-CT or MRI after some time has passed by (4 to 8 weeks). Valuable time is lost.

For this reason Metavectum has developed an analytical system which monitors the therapy administered by the attending doctor promptly (daily or weekly) in such a way that an analysis of the cellular metabolism by means of urine or blood samples gives prompt information on whether the therapy is progressing successfully, whether it is less helpful or whether it is accompanied by cellular side effects which could make a therapy change necessary.